BidaskClub upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a buy rating in a research note released on Thursday morning.
Several other equities analysts have also recently issued reports on the company. ValuEngine raised Ascendis Pharma A/S from a buy rating to a strong-buy rating in a report on Wednesday, December 5th. Credit Suisse Group lifted their price objective on Ascendis Pharma A/S from $80.00 to $86.00 and gave the stock an outperform rating in a report on Thursday, November 29th. Finally, Zacks Investment Research cut Ascendis Pharma A/S from a buy rating to a hold rating in a report on Tuesday, November 13th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $77.56.
Shares of ASND traded down $1.43 during mid-day trading on Thursday, hitting $69.25. The company’s stock had a trading volume of 127,923 shares, compared to its average volume of 239,337. The stock has a market capitalization of $2.94 billion, a P/E ratio of -15.99 and a beta of 0.86. Ascendis Pharma A/S has a 1-year low of $45.17 and a 1-year high of $76.99.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, November 28th. The biotechnology company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.29. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.16 million. Ascendis Pharma A/S had a negative return on equity of 45.44% and a negative net margin of 38,569.44%. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -3.9 EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in ASND. PNC Financial Services Group Inc. purchased a new position in Ascendis Pharma A/S during the second quarter worth $350,000. Glen Harbor Capital Management LLC increased its position in Ascendis Pharma A/S by 12.1% during the second quarter. Glen Harbor Capital Management LLC now owns 8,848 shares of the biotechnology company’s stock worth $589,000 after buying an additional 952 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Ascendis Pharma A/S by 153.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,444 shares of the biotechnology company’s stock worth $598,000 after buying an additional 5,107 shares in the last quarter. Advisory Research Inc. purchased a new position in Ascendis Pharma A/S during the third quarter worth $838,000. Finally, DekaBank Deutsche Girozentrale increased its position in Ascendis Pharma A/S by 464.6% during the third quarter. DekaBank Deutsche Girozentrale now owns 27,100 shares of the biotechnology company’s stock worth $1,916,000 after buying an additional 22,300 shares in the last quarter. 95.60% of the stock is owned by institutional investors.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Featured Article: The Discount Rate – What You Need to Know
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.